Medication Assisted Treatment Statistics for Recovery
Key Takeaways
- Only 25.1% of U.S. adults who needed opioid use disorder treatment in 2022 received medication, leaving three out of four people without the care backed by the strongest evidence 1.
- Agonist therapy with methadone or buprenorphine is associated with roughly a 50% reduction in mortality, while relapse rates without MAT run 65-80% within the first month 13, 14.
- Buprenorphine, methadone, and naltrexone all carry FDA approval, but the right fit depends on opioid history, schedule, transportation, and what has been tried before — not a ranking 6, 4.
- Transitions are where recovery breaks down; ask a prescriber which medication fits, how soon you can start, whether the pharmacy stocks it, and what the first 72 hours after discharge look like 2, 1.
What the numbers actually say about MAT
If you are reading this, you are already doing something the data says most people don’t get to do: looking hard at the evidence before making a decision about your own recovery. That counts.
Medication for opioid use disorder works. Federal agencies and peer-reviewed studies agree that buprenorphine, methadone, and naltrexone — the three FDA-approved options — reduce overdose deaths and improve survival when you stay on them 6, 7. Yet, in 2022, only 25.1% of U.S. adults who needed treatment for opioid use disorder actually received medication for it 1. This means three out of four people who needed this care did not get the part of treatment with the strongest evidence behind it.
This gap is not about whether the medicine works. It is about pharmacies that don’t stock it, prescribers who hesitate, prior authorizations that stall, and stigma that whispers you should just tough it out 1. None of that is your fault, and none of it changes what the science shows.
The pages ahead walk you through the numbers — who gets MAT, how much it lowers your risk, why the system loses people at the handoffs, and what to ask for so you end up inside that 25%, not outside it.
The cascade of care: who needs MAT, who gets it
From need to medication: a four-step drop-off
Picture the path from opioid use disorder to medication as four steps, each one losing people along the way:
- Needing treatment.
- Knowing you need it and being willing to consider help.
- Actually reaching a treatment setting.
- Receiving one of the three FDA-approved medications.
The CDC’s 2022 population estimate makes the drop-off concrete. In that year, 3.7% of U.S. adults — millions of people — needed treatment for opioid use disorder. Of everyone who needed it, just 25.1% received medication. And among the smaller group who got any kind of treatment at all, only 45.5% received MOUD 1. Even after making it through the hardest parts — admitting the problem, finding a program, showing up — fewer than half of the people in the room are offered the part of care with the strongest evidence behind it.
That is not a story about willpower. It is a story about a system that loses people at every transfer. Some of the loss happens before anyone calls a clinic, often because of stigma or fear about what treatment will mean for work, family, or custody. Some happens at intake, when a counselor or program leans toward abstinence-only models and skips the medication conversation entirely 1. Some happens at the pharmacy counter or at the prior-authorization desk.
If you are weighing MAT right now, you are already further along this cascade than most. The question is whether the program you choose treats medication as the default for opioid use disorder — or as an optional add-on you have to ask for.
What ‘fewer than 1 in 5’ looks like in practice
NIDA frames the same problem from another angle: fewer than 1 in 5 people with opioid use disorder are treated with these medications 7. That framing is useful because it strips away the cascade math and just tells you the end state. Five people sit at a kitchen table, all living with OUD. One of them is on buprenorphine, methadone, or naltrexone. The other four are not.
What does that look like up close? It looks like a brother who went through a 28-day program last spring and was told medication was a crutch. It looks like a coworker who tried to get a buprenorphine prescription and was sent home with a referral that never connected. It looks like someone who wanted methadone but the nearest opioid treatment program was an hour each way, every morning, and the job would not flex.
None of those people are statistical failures. They are people the system did not hold onto. Knowing that is not meant to discourage you — it is meant to sharpen what you ask for. If you want to be one of the four-out-of-five who currently are not getting medication, the conversation with a prescriber starts there: I want MAT, I want to understand which of the three medications fits my situation, and I want a plan for what happens if my first option does not work.
The mortality math: how much MAT changes the odds
Roughly half: agonist therapy and overdose death
Here is the number that does the most work in this whole article: agonist therapy for opioid use disorder is associated with an estimated 50% reduction in mortality 13. A 2024 study reached the same headline figure — about a 50% drop in opioid-related mortality with MAT 12. Two independent reads, one finding. That is rare in addiction research and worth pausing on.
Scope matters, so let’s be specific. The 50% figure comes from synthesis evidence on methadone and buprenorphine — the two agonist medications. It compares people retained on medication to people with opioid use disorder who are not. It is a population-level estimate, not a personal guarantee, and the benefit depends on staying on the medication long enough for it to do its work 13. The same evidence review notes that data on extended-release naltrexone’s mortality benefit is thinner than for the agonists 13.
What does cutting your mortality risk roughly in half actually mean for you? It means the medication is doing two things at once: it stabilizes the receptors that drive cravings and withdrawal, and it lowers the chance that a single relapse becomes a fatal overdose. CDC clinical guidance is direct about this — medication treatment of OUD has been associated with reduced overdose and overall mortality, and that is why it is the recommended first-line approach 2.
You do not have to feel certain to start. You only have to be willing to take the first step where the math is on your side.
The first month without medication
The other number worth knowing is what happens when medication is not part of the picture. Without MAT, opioid relapse rates run between 65% and 80% just one month after treatment ends 14. Two out of three people, sometimes four out of five, are using again within thirty days.
Read that as a system finding, not a verdict on anyone’s character. The brain changes that come with opioid use disorder do not reset in twenty-eight days. Cravings spike, sleep is broken, and the receptors that opioids were occupying are still asking for something. Willpower is real, but it is not built to do that job alone.
The 65-to-80% number is not meant to scare you. It is the rhetorical hinge: medication is not a sign that you have failed at recovery. It is the thing that holds the floor steady underneath you during the month when the floor is most likely to give way. If you have relapsed before — once, or many times — that is information about the system, not a final word on you.
The three medications, side by side
The FDA has approved three medications for opioid use disorder: buprenorphine, methadone, and naltrexone 6. They all work, they are all considered safe for long-term use — from months to a lifetime — and they all belong inside the conversation when you talk to a prescriber 4. What they do not do is work the same way, and that matters when you and a clinician are deciding which one fits your life.
Buprenorphine is a partial agonist. It activates the same opioid receptors heroin and fentanyl reach, but only partway, which takes the edge off cravings and withdrawal without producing the same high. It can be prescribed in a regular doctor’s office or clinic when state law allows, which makes it the most accessible of the three 2. In a 2023 cohort study where only 10.38% of patients with OUD received any MAT, buprenorphine stood out as the medication associated with the lowest risk of overdose-related hospitalization or ER visits among the drugs studied 11. That is a meaningful signal if your priority is staying out of a crisis setting.
Methadone is a full agonist. It fully activates the receptors and, for people with heavier or longer opioid histories, often holds steady where buprenorphine cannot. The trade-off is the setting: methadone for OUD is dispensed through federally regulated opioid treatment programs, which historically has meant daily clinic visits, especially early on 5. The evidence base for methadone is deep — it is one of the agonist therapies linked to that roughly 50% mortality reduction in the synthesis literature 13.
Naltrexone is an antagonist. It blocks opioid receptors instead of activating them, so it does not satisfy cravings the way the agonists do — it makes opioids unable to produce a high if you use. It requires being fully off opioids before starting, which is the piece that trips people up. The extended-release injection removes the daily-pill decision, but the evidence base for mortality benefit is thinner than it is for the agonists 13.
None of this is a ranking. It is a map. The right medication is the one a prescriber matches to your history, your work, your transportation, and what has or has not worked before.
Why the 75% don’t get medication
Pharmacies, prior auth, and provider bias
The gap between needing medication and holding the prescription bottle is not one wall. It is a hallway with several doors, and any one of them can stay shut.
Start with the pharmacy. A prescriber writes for buprenorphine, and the pharmacy down the street does not stock it — or stocks a different formulation, or limits how many patients it will dispense to in a month. CDC’s own analysis of why so few adults receive MOUD names pharmacy stocking issues as part of the access problem, alongside payer prior authorization requirements that delay or block the prescription entirely 1. A delay of a few days does not sound like much. During early withdrawal, it can be the difference between staying with the plan and going back to what you know works fast.
Then there is the provider. Some clinicians and programs still lean toward abstinence-only models and frame medication as a crutch instead of as care 1. You may have heard a version of this yourself — from a counselor, a family member, or even a doctor. CDC is explicit that medication is associated with reduced overdose and overall mortality, and that lack of psychosocial treatment should not delay starting MOUD 2. If a program tells you medication is something to consider later, that is a signal to ask whether their default matches the evidence — or to find a setting where it does.
Geography and the rural gap
Where you live shapes what you can get. Buprenorphine is the most portable of the three medications because it can be prescribed in a regular office or clinic, but the prescribers and pharmacies that actually carry it are not spread evenly across the map 2. Peer-reviewed work on filling the treatment gap has zeroed in on geographic expansion of buprenorphine as one of the central levers for closing access disparities, especially outside major metro areas 10.
Methadone is harder still. Because methadone for OUD is dispensed only through federally regulated opioid treatment programs, and many rural counties have none, getting on it can mean driving an hour or more each way, every morning, especially in the first weeks 5. That is not a moral test. It is a logistics problem that has ended treatment plans for people with jobs, kids, or unreliable cars. If you live somewhere with limited options, telehealth-enabled buprenorphine and traveling for a stretch of structured care are both worth asking about before you assume the door is closed.
What changed in 2024: SAMHSA’s final rule
The rules are not frozen. In early 2024, SAMHSA issued a final rule updating the regulations that govern opioid treatment programs — the federal framework that controls how methadone and some other OUD services are delivered 15. The update is meant to add flexibility to a system that for decades has run on rigid daily-dosing requirements and tight take-home limits.
What that means for you depends on the program you walk into, because rules give permission but do not force adoption. The practical question to ask is whether the OTP near you has updated its take-home schedule, telehealth intake, and dosing flexibility under the new framework. SAMHSA’s broader page on statutes and regulations is the federal reference point if you or a family member want to check what is currently allowed 5. A program that has actually moved with the rule looks different from one that has not.
Continuity of care: why transitions are dangerous and fixable
Recovery rarely fails in the middle. It fails at the seams — the day you leave residential, the morning after detox, the week you walk out of a county jail with a paper bag of belongings and no prescription. Every handoff is a place where medication access can drop, and tolerance has already dropped with it. That combination is what makes transitions the most dangerous stretch of any treatment plan.
The clearest evidence for fixing those seams comes from correctional health. When jails actually offer medication for opioid use disorder, post-release outcomes change sharply. A 2025 NIH-reported study of jail-based MOUD found:
- 52% lower risk of fatal opioid overdose
- 24% lower risk of non-fatal overdose
- 12% lower risk of reincarceration after release 9
Three different outcomes, all moving in the same direction, all tied to one variable: whether the medication continued across the handoff.
You may never see the inside of a jail, but the principle holds for any transition you do face. Coming off a residential stay without a buprenorphine prescription in hand, or leaving an inpatient detox with a follow-up appointment two weeks out, is the same structural problem on a smaller scale. Tolerance is down, the receptors are still asking, and the medication that holds the floor steady is not in the bottle yet.
The fix is unglamorous and concrete:
- Induction before discharge
- A prescription that travels with you
- A confirmed next appointment within days
- A pharmacy you have already called to confirm stock
CDC guidance is direct that medication treatment of OUD is associated with reduced overdose and overall mortality, and that lack of psychosocial treatment should not delay starting it 2. If a program is planning your discharge and the medication piece is vague, that is the moment to slow down and ask what the first 72 hours actually look like.
When PTSD, depression, or anxiety are also in the room
For a lot of people considering MAT, opioid use disorder is not the only thing showing up to the appointment. Trauma is there. So is the depression that arrived years before the first prescription, or the anxiety that made the pills feel like the only thing that quieted the noise. None of that disqualifies you from medication for OUD. It changes what good care looks like.
SAMHSA frames buprenorphine, methadone, and naltrexone as part of a whole-patient approach, meaning the medication is one piece of treatment that also addresses what is going on around it 4. CDC clinical guidance is just as direct on the order of operations: a lack of psychosocial treatment should not delay starting MOUD, and the medication is associated with reduced overdose and overall mortality on its own 2. You do not have to have your mental health perfectly sorted before you start. You start, and the trauma work, the antidepressant question, the sleep, the therapy — those move in alongside it.
What you want to ask is whether the program treats co-occurring conditions in the same building, with clinicians who talk to each other, or whether they hand you a referral list and call it a plan. Integrated care is the standard, not a premium add-on.
Questions to bring to a prescriber
Walking into an appointment with specific questions changes the conversation. You stop being someone a clinician is sorting and start being someone they are planning with. Here is what to ask, and why each question matters.
Which of the three medications do you think fits my history, and why? Buprenorphine, methadone, and naltrexone all have FDA approval, and the right choice depends on your opioid history, your work schedule, your transportation, and what you have tried before 6, 4. A prescriber who has a real answer here is treating you as the specific person you are.
How soon can I start? CDC guidance is direct that a lack of psychosocial treatment should not delay starting medication 2. If the answer involves waiting weeks for counseling to begin first, that is worth pushing back on.
Have you confirmed the pharmacy stocks it? Prescriptions that cannot be filled the same day are one of the documented reasons people fall out of the cascade 1. Ask who calls ahead.
What happens at transitions? If you are leaving detox, residential, or any structured setting, ask exactly what the first 72 hours look like — induction, prescription in hand, confirmed follow-up.
How do you handle PTSD, depression, or anxiety alongside this? Co-occurring conditions deserve a team that talks to itself, not a referral list 4.
Ready to Start with Evidence-Based MAT Support?
Connect now for guidance on starting medication-assisted treatment and personalized recovery options.
Talk With Someone Who Understands MAT Recovery
Get experienced guidance tailored to your MAT and recovery needs, with support every step of the way.
Frequently Asked Questions
Is medication-assisted treatment just replacing one drug with another?
No. Buprenorphine, methadone, and naltrexone are FDA-approved medications that stabilize the brain changes opioid use disorder causes — they do not produce the same high as heroin or fentanyl when taken as prescribed 6. SAMHSA is direct that these medications are part of a whole-patient approach to treatment, not a substitute drug 4. Calling MAT a swap ignores what the medication actually does inside a treatment plan.
How much does MAT actually reduce the risk of overdose death?
The synthesis evidence on agonist therapy — methadone and buprenorphine — points to roughly a 50% reduction in mortality compared to people with opioid use disorder who are not on medication 13. CDC clinical guidance also states that medication treatment of OUD has been associated with reduced overdose and overall mortality, which is why it is the recommended first-line approach 2. The benefit depends on staying on the medication.
Which medication is right for me: buprenorphine, methadone, or naltrexone?
There is no universal answer — the FDA approves all three, and the right fit depends on your opioid history, daily schedule, and what has worked before 6. Buprenorphine is often the most accessible because it can be prescribed in regular medical offices when state law permits 2. Methadone, dispensed through opioid treatment programs, has decades of evidence behind it 13. Ask a prescriber to match the medication to you.
Can I just detox and skip the medication?
CDC explicitly advises against detoxification on its own because it increases the risk of resuming drug use, overdose, and overdose death — tolerance drops fast while the triggers that drove use have not changed 2. Without MAT, opioid relapse rates run between 65% and 80% in the first month after treatment ends 14. A clean week followed by the old dose is one of the most dangerous combinations there is.
What if I also have PTSD, depression, or anxiety?
You can still start MAT. CDC guidance says a lack of psychosocial treatment should not delay medication for OUD, and the medication’s mortality benefit holds on its own 2. SAMHSA frames buprenorphine, methadone, and naltrexone as part of a whole-patient approach that includes counseling and behavioral therapy 4. Look for a program that treats co-occurring conditions in the same place, with clinicians who actually coordinate, rather than handing you a referral list.
How long will I need to stay on medication?
There is no set endpoint. SAMHSA states these medications are safe for long-term use, ranging from months to a lifetime 4. Evidence reviews show that longer retention on medication for OUD is associated with better outcomes — staying on is the variable that drives the mortality benefit, not how fast you taper off 13. The decision is between you and a prescriber, revisited over time. There is no prize for stopping early.
References
- Treatment for Opioid Use Disorder: Population Estimates — United States, 2022. https://www.cdc.gov/mmwr/volumes/73/wr/mm7325a1.htm
- Opioid Use Disorder: Treating | Overdose Prevention. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html
- Treatment of Opioid Use Disorder | Overdose Prevention. https://www.cdc.gov/overdose-prevention/treatment/opioid-use-disorder.html
- Treatment Options for Substance Use Disorder – SAMHSA. https://www.samhsa.gov/substance-use/treatment/options
- Substance Use Disorders: Statutes, Regulations, and Guidelines. https://www.samhsa.gov/substance-use/treatment/statutes-regulations-guidelines
- Information about Medications for Opioid Use Disorder (MOUD) – FDA. https://www.fda.gov/drugs/information-drug-class/information-about-medications-opioid-use-disorder-moud
- Medications for Opioid Use Disorder | National Institute on Drug Abuse. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
- Medications for Opioid Use Disorder (MOUD) Study – CDC. https://www.cdc.gov/overdose-prevention/data-research/facts-stats/moud-study.html
- Treating opioid addiction in jails improves treatment engagement, reduces overdose deaths and reincarceration. https://www.nih.gov/news-events/news-releases/treating-opioid-addiction-jails-improves-treatment-engagement-reduces-overdose-deaths-reincarceration
- Filling the Treatment Gap: Geographic Expansion of Buprenorphine …. https://pmc.ncbi.nlm.nih.gov/articles/PMC11994037/
- Association of Medication-Assisted Therapy and Risk of Drug …. https://pmc.ncbi.nlm.nih.gov/articles/PMC10519365/
- The impact of medication-assisted treatment for opioid use disorder …. https://pubmed.ncbi.nlm.nih.gov/39345354
- The Effectiveness of Medication-Based Treatment for Opioid Use Disorder. https://www.ncbi.nlm.nih.gov/books/NBK541393/
- MEDICATION-ASSISTED TREATMENT. https://ncsacw.acf.gov/files/mat-primer-508.pdf
- SAMHSA releases final rule on opioid use disorder treatment. https://www.aha.org/news/headline/2024-01-31-samhsa-releases-final-rule-opioid-use-disorder-treatment
